Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7P1J4)

• Drug Name: Benralizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1]
Chronic obstructive pulmonary disease	CA22	Phase 3	[2]

• Cross-matching ID: TTD Drug ID: DM7P1J4

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-5 (IL5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mepolizumab	DMW2GEJ	Severe asthma	CA23	Approved	[5]
Reslizumab	DM0AUCH	Severe asthma	CA23	Approved	[6]
GSK3511294	DMWKSFY	Asthma	CA23	Phase 3	[7]
Depemokimab	DMG9VHN	Asthma	CA23	Phase 3	[7]
SOPHORICOSIDE	DM4A0NP	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Interleukin 5 receptor alpha (IL5RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CSL311	DMC21G0	Asthma	CA23	Phase 1	[9]
YM90709	DML5DU0	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 5 receptor alpha (IL5RA)	TTXH9AD	IL5RA_HUMAN	Modulator	[3]
Interleukin-5 (IL5)	TTPREZD	IL5_HUMAN	Modulator	[4]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7674).
• [3] Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8.
• [4] Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma
• [5] Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30.
• [6] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [7] A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.
• [8] Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9.
• [9] Anti-beta(c) mAb CSL311 inhibits human nasal polyp pathophysiology in a humanized mouse xenograft model. Allergy. 2020 Feb;75(2):475-478.
• [10] Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int Immunopharmacol. 2002 Nov;2(12):1693-702.